Criteo (NasdaqGS:CRTO) Q3 2025 Earnings Call October 29, 2025 08:00 AM ET Company ParticipantsYgal Arounian - Director and Internet Equity ResearcMark Kelley - Managing DirectorMelanie Dambre - VP of Investor RelationsDouglas Anmuth - Head of US Internet Equity ResearchMatthew Cost - Executive Director in Equity ResearchTodd Parsons - Chief Product OfficerSarah Glickman - CFOMichael Komasinski - CEORichard Kramer - Founder and Managing DirectorConference Call ParticipantsTim Nolan - Senior AnalystMark Zguto ...

Financial Data and Key Metrics Changes - Revenue for Q3 2025 reached $60.1 million, reflecting a 23.5% increase compared to Q3 2024 and a 6% sequential increase from Q2 2025 [7][19] - Gross profit for the quarter was $46 million, up from $36.4 million in Q3 2024, resulting in a gross margin of 76.6%, an increase from 74.9% year-over-year [21][22] - Net income for the quarter was $0.7 million or $0.01 per share, compared to a net loss of $1.9 million or $0.04 per share in Q3 2024 [23] - Adjusted net income was $6.1 million or $0.12 per share, compared to $3.1 million or $0.07 per share in the same period last year [24] Business Line Data and Key Metrics Changes - Strong revenue growth was driven by the Avance Nerve Graft and the adoption of the nerve repair algorithm across target markets, with double-digit growth in extremities, oromaxillofacial, and breast markets [7][8] - Active breast ReSensation programs increased by 7% from Q3 2024, with 281 surgeons performing procedures in Q3 2025, representing a 20% increase [13] - The company trained 97 surgeons in extremities year-to-date, exceeding training targets in oromaxillofacial and head and neck markets [12][13] Market Data and Key Metrics Changes - Coverage among commercial payers increased to over 64%, with an estimated 18.1 million additional lives covered for nerve repair using synthetic conduits or allografts [16] - The company is actively engaging with national payers to transition from investigational to standard coverage, reflecting ongoing efforts to expand access [42] Company Strategy and Development Direction - The company aims to generate at least 66% of total revenue growth from high-potential accounts, with a focus on expanding presence and improving salesforce productivity [9] - Innovation remains critical to long-term growth, with ongoing clinical research and development initiatives to support nerve care [14] - The company plans to continue incremental hiring across target markets to enhance coverage and develop nerve care usage [82] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strategic plan and the ability to deliver growth consistent with guidance, despite slight underperformance in high-potential accounts due to the transition from case stock sales [7][10] - The FDA has extended the PDUFA goal date for the Biologics License Application for Avance Nerve Graft to December 5, 2025, which is expected to secure market exclusivity [18] Other Important Information - The company raised its revenue growth guidance for 2025 to at least 19%, expecting revenue of at least $222.8 million [25] - Operating expenses increased to $44.1 million, but as a percentage of revenue, they decreased, indicating improved operating leverage [22] Q&A Session Summary Question: Insights on Q4 revenue expectations and case stock sales program impact - Management indicated that the $1.6 million revenue increase in Q3 was related to the transition from case stock sales and advised excluding this from Q4 models [30] Question: Comments on BLA and labeling expectations - Management confirmed that the FDA is expected to discuss labeling in November, with the final BLA decision still targeted for December 5 [91] Question: Coverage expansion and its impact post-BLA approval - Management noted that BLA approval would support market development efforts but cautioned against expecting immediate widespread adoption [94]

ESAB (NYSE:ESAB) Q3 2025 Earnings Call October 29, 2025 08:00 AM ET Company ParticipantsBryan Blair - Managing DirectorShyam Kambeyanda - CEOTami Zakaria - Executive DirectorKevin Johnson - CFOMircea Dobre - Associate Director of ResearchNeal Burk - Director of Industrials Equity ResearchMark Barbalato - VP of Investor RelationsConference Call ParticipantsNathan Jones - Managing Director and Industrials Equity AnalystOperatorThank you for standing by and welcome to the ESAB Third Quarter 2025 Earnings Confe ...

CVS Health (NYSE:CVS) Q3 2025 Earnings Call October 29, 2025 08:00 AM ET Company ParticipantsAndrew Mok - Director of Equity ResearchLisa Gill - Managing DirectorBrian Newman - CFOPrem Shah - EVP, Chief Pharmacy Officer, and President, Pharmacy and Consumer WellnessSteve Nelson - EVP and President of AetnaLarry McGrath - Chief Strategy OfficerDavid Joyner - President and CEOConference Call ParticipantsMichael Cherny - Senior Managing Director and Senior Research AnalystKevin Caliendo - Healthcare Equity Res ...

Oatly Group (NasdaqGS:OTLY) Q3 2025 Earnings Call October 29, 2025 08:00 AM ET Company ParticipantsDaniel Ordoñez - Global President and COOMarie-José David - CFOBrian Kearney - Head of Investor RelationsJean-Christophe Flatin - CEOConference Call ParticipantsSamu Wilhelmsson - Credit Research AnalystAndrew Lazar - Stock AnalystDara Mohsenian - MD and Senior Equity AnalystTom Palmer - Equity Research AnalystJohn Baumgartner - Senior Research AnalystOperatorGood day and welcome to the Oatly Group AB third qu ...

SiteOne Landscape Supply (NYSE:SITE) Q3 2025 Earnings Call October 29, 2025 08:00 AM ET Company ParticipantsScott Salmon - EVP of Strategy and DevelopmentJohn Guthrie - EVP, CFO, and Assistant SecretaryDoug Black - Chairman and CEOEric Elema - VP of Finance and Corporate ControllerConference Call ParticipantsDavid Manthey - AnalystJeffrey Stevenson - AnalystAndrew Carter - AnalystRyan Merkel - AnalystCharles Perron-Pich - AnalystDamian Karas - AnalystJulian Nirmal - AnalystNone - AnalystElizabeth Langan - A ...

Financial Data and Key Metrics Changes - Third quarter net revenues were $931 million, an increase of more than 2% from $910 million in the year-ago period [16] - Adjusted EPS was $0.42 compared to $0.41 in the year-ago period, reflecting lower interest costs and tax initiatives [17] - Consolidated adjusted EBITDA was $168 million compared to $171 million in the year-ago period [17] Business Line Data and Key Metrics Changes - Retail revenue of $864 million increased 1% compared to the third quarter of 2023, with retail volume growing 1% excluding foam products [16] - Reynolds Wrap retail sales were up 7%, with volumes outperforming the category [9] - Hefty Waste Bags saw retail takeaways increase by 9%, outperforming the category by 10 points [31] Market Data and Key Metrics Changes - The operating environment remains challenging, particularly for low and middle-income consumers facing cost inflation [8] - The company noted that inflation remains around 3%, above the Fed's target of 2% [33] - Consumer sentiment has declined, with double-digit decreases year to date heading into the holidays [33] Company Strategy and Development Direction - The company is focusing on innovation and revenue growth management to drive share gains and profitability [39] - A new Chief Commercial Officer is leading growth programs to enhance market share across major customers [9] - The company is investing in high-return projects to support growth and drive margin improvements [21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in retail trends and the effectiveness of implemented programs to drive near and long-term results [19] - The company anticipates net revenues to be flat to down 1% for the full year compared to 2024 [19] - Management highlighted the importance of maintaining cost discipline in all areas, including SG&A [19] Other Important Information - The company is making progress in managing manufacturing, supply chain, and SG&A costs while driving market share [7] - New product innovations, such as Reynolds Kitchens Air Fryer liners, have been recognized for their growth potential [10] - The company is positioned well within its target leverage range of 2x-2.5x EBITDA, allowing for continued investment in growth opportunities [21] Q&A Session Summary Question: How do you see the setup for the important holiday season in terms of promotional intensity and consumer behavior? - Management noted increased promotional activity in waste and food bags but feels confident in navigating the promotional environment [31][32] - Consumer sentiment remains under pressure, with inflation and cooling labor markets impacting lower-income demographics [33][34] Question: Can you elaborate on the risk of retailers shifting store brands to other suppliers? - Management flagged this risk due to economic challenges and uncertainty in supply chains, but expects to win more than lose as a US-centric manufacturer [34] Question: What is the grand plan related to operational capabilities and long-term growth? - The company is focused on driving growth through innovation, revenue growth management, and share gains at the customer level [39] Question: What is the outlook for the tableware business and foam products? - The tableware business is down primarily due to foam headwinds, but profitability has increased despite volume declines [42][43] Question: How is the Hefty Waste and Storage segment performing in terms of profitability and distribution? - The segment continues to perform well, with significant volume growth and effective management of promotional activities [46][47] Question: What is the current state of consumer behavior regarding dining out versus cooking at home? - There are modest tailwinds from increased cooking at home, but rising prices in the marketplace are also a factor [64]

Bausch + Lomb (NYSE:BLCO) Q3 2025 Earnings Call October 29, 2025 08:00 AM ET Company ParticipantsPatrick Wood - Managing DirectorSam Eldessouky - CFO and EVPTom Stephan - VP of Healthcare Equity ResearchYehia Hashad - Head of R&D and Chief Medical OfficerDavid Roman - Managing DirectorBrent Saunders - Chairman and CEOGeorge Gadkowski - VP and Head of Investor Relations and Business InsightsLily Lazada - VP of Equity ResearchJoanne Wuensch - Managing DirectorConference Call ParticipantsYoung Li - SVP and Equ ...

Extreme Networks (NasdaqGS:EXTR) Q1 2026 Earnings Call October 29, 2025 08:00 AM ET Company ParticipantsStan Kovler - SVP of Finance and Corporate DevelopmentKevin Rhodes - EVP and CFOEd Meyercord - President and CEOConference Call ParticipantsChris Schwab - AnalystMike Genovese - Senior Research AnalystDave King - AnalystRyan Koontz - Senior Research AnalystDavid Vogt - Senior Equity AnalystEric Martinuzzi - Senior Research AnalystOperatorThank you for standing by. My name is Rebecca, and I will be your co ...

Financial Data and Key Metrics Changes - Total net revenue for Q3 2025 was $49.7 million, an increase of $7.4 million or 17% compared to the prior year, primarily due to higher U.S. sales [21] - Net product revenue was $48.6 million, reflecting a $6.7 million or 16% increase [21] - U.S. net product revenue reached $40.9 million, a significant increase of $10.3 million or 34%, driven by a change in customer mix and increased volume [22] - Operating loss for Q3 2025 was $11.1 million, which is $14.1 million or 56% lower than Q3 2024, indicating improved operational efficiency [25] - Operating margin improved to -22% from -60% in the prior year [25] - Cash and investments at the end of the quarter totaled $286.6 million, with no debt and working capital of $446 million [26] Business Line Data and Key Metrics Changes - The transition to a partnered model with Recordati has begun to show results, with product revenue from Europe at $4.1 million, consistent with the prior year [22][23] - Revenue from the rest of the world was $3.6 million, a decline from the prior year, attributed to variability in supply shipments and market demand [23][50] - SG&A expenses were reduced to $19.7 million, a decrease of $17.2 million or 47% compared to the prior year [24] Market Data and Key Metrics Changes - VASCEPA maintained over 50% market share in the IPE market in the U.S., demonstrating resilience five years post-generic entry [11] - The company anticipates that Recordati will fully manage European commercialization by the end of 2025, with sustained momentum in demand across all commercialized European markets [9][10] Company Strategy and Development Direction - The partnership with Recordati marks a strategic shift to a fully partnered commercial model in international markets, aiming to leverage expertise across nearly 100 markets [5][6] - The company is focused on reducing the cardiovascular disease burden globally, with a commitment to operational efficiency and cost savings of $70 million over the next year [8] - The transition to a partnered model is expected to enhance revenue generation and operational efficiency, with a focus on maximizing the clinical impact of VASCEPA [12][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strategic actions taken and the potential for growth, particularly in underpenetrated markets [19] - The company is optimistic about achieving positive free cash flow by 2026, supported by a rightsized operating footprint and improved operating margins [26] - The FDA's recent actions regarding fenofibrates are seen as an opportunity to shift clinical practice towards more effective therapies like VASCEPA [14][17] Other Important Information - Restructuring expenses totaled $9.4 million for the quarter, with a total of $32.2 million incurred to date [25] - The company is committed to advancing cardiovascular care through a strong presence at major medical meetings, including the European Society of Cardiology conference [12] Q&A Session Summary Question: U.S. net price trajectory for the back half of 2025 and into 2026 - Management anticipates U.S. net prices to remain consistent for the remainder of 2025, with ongoing negotiations for rebate percentages for 2026 [28][30] Question: Future milestone payments from Recordati - Milestone payments are based on sales performance, triggered as Recordati surpasses $100 million in sales [30] Question: Decline in rest of world revenue - The decline is attributed to variability in supply shipments and the absence of larger launches in the current quarter [48][50]